Put Options

9 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$10.52 - $14.35 $3,156 - $4,305
300 Added 0.51%
59,100 $662,000
Q2 2024

Aug 14, 2024

SELL
$10.58 - $15.61 $1,058 - $1,561
-100 Reduced 0.17%
58,800 $632,000
Q1 2024

May 15, 2024

BUY
$14.14 - $19.59 $281,386 - $389,841
19,900 Added 51.03%
58,900 $877,000
Q4 2023

Feb 14, 2024

BUY
$12.85 - $19.15 $129,785 - $193,415
10,100 Added 34.95%
39,000 $706,000
Q3 2023

Nov 14, 2023

SELL
$14.58 - $20.15 $80,190 - $110,824
-5,500 Reduced 15.99%
28,900 $501,000
Q2 2023

Aug 14, 2023

SELL
$18.12 - $30.56 $239,184 - $403,392
-13,200 Reduced 27.73%
34,400 $623,000
Q1 2023

May 15, 2023

BUY
$18.73 - $36.26 $256,601 - $496,762
13,700 Added 40.41%
47,600 $1.27 Million
Q4 2022

Feb 14, 2023

BUY
$17.0 - $25.43 $79,900 - $119,521
4,700 Added 16.1%
33,900 $655,000
Q3 2022

Nov 14, 2022

BUY
$7.67 - $24.23 $223,964 - $707,516
29,200 New
29,200 $610,000

Others Institutions Holding PLRX

About PLIANT THERAPEUTICS, INC.


  • Ticker PLRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,682,000
  • Market Cap $649M
  • Description
  • Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...
More about PLRX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.